Bradley J. Katz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bradley J. Katz has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Kathleen B. Digre
Department of Ophthalmology and Visual Sciences University of Utah Salt Lake City Utah USA
13 shared publicationsJudith E.A. Warner
Department of Ophthalmology and Visual Sciences, John A Moran Eye Center, University of Utah Health, Salt Lake City, UT, USA
8 shared publicationsAlison V. Crum
Department of Ophthalmology and Visual Sciences, John A Moran Eye Center, University of Utah Health, Salt Lake City, UT, USA
7 shared publications- Kathleen B. Digre
Department of Neurology University of Utah School of Medicine Salt Lake City UT USA
7 shared publications Judith E. A. Warner
John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, Department of Neurology, University of Utah Health, Salt Lake City
6 shared publications- Judith E. A. Warner
Moran Eye Center, University of Utah, Salt lake City, Utah
5 shared publications
Latest Publications
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (4) , 515-520
Use of a Virtual Reality Visual Field Device to Improve Quality of Care in the Emergency Department and Inpatient Setting
Background: Automated visual field testing is an essential diagnostic and disease monitoring tool for many neuro-ophthalmic disorders. Most commonly, automated devices are stationary and located in ophthalmology clinics. Thus, formal visual field testing has been limited in the hospital setting until recent availability of virtual reality visual field testing. In this study, we report our experience with the use of a virtual visual field (VVF) device in the Emergency Department (ED) and inpatient hospital settings. Methods: We performed a retrospective chart review of our use of a VVF device in the ED and inpatient hospital setting from February 2020 to September 2022. We report our experience and the impact on patient care with use of the VVF device. Results: One hundred fifty patients (aged 10–85 years) and 162 visual field encounters were identified. Patients were most commonly located on the regular hospital ward (51%), followed by the intensive care unit (28%), and ED (21%). The VVF prevented the need for a trip to the outpatient ophthalmology clinic in 100% of encounters of patients with vision-threatening papilledema. Use of the VVF provided a more detailed, baseline examination at bedside in 61% of all encounters. A bedside pre- and postoperative visual field assessment was achieved in 14% of encounters. The VVF changed management in 70% of encounters. Conclusions: In our experience, use of the VVF has improved the quality of care for inpatients with neuro-ophthalmic conditions. A significant impact of the VVF was increased safety by preventing the need to transport patients to the outpatient setting for visual field monitoring, especially patients with vision-threatening papilledema and lumbar drains. The VVF made formal visual testing available to patients with mobility restrictions and patients undergoing neurosurgical procedures. Owing to improvement in quality of patient care, the VVF analyzer has become a mainstay of the examination of patients in the ED and hospital.
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (4) , 515-520
Use of a Virtual Reality Visual Field Device to Improve Quality of Care in the Emergency Department and Inpatient Setting
Background: Automated visual field testing is an essential diagnostic and disease monitoring tool for many neuro-ophthalmic disorders. Most commonly, automated devices are stationary and located in ophthalmology clinics. Thus, formal visual field testing has been limited in the hospital setting until recent availability of virtual reality visual field testing. In this study, we report our experience with the use of a virtual visual field (VVF) device in the Emergency Department (ED) and inpatient hospital settings. Methods: We performed a retrospective chart review of our use of a VVF device in the ED and inpatient hospital setting from February 2020 to September 2022. We report our experience and the impact on patient care with use of the VVF device. Results: One hundred fifty patients (aged 10–85 years) and 162 visual field encounters were identified. Patients were most commonly located on the regular hospital ward (51%), followed by the intensive care unit (28%), and ED (21%). The VVF prevented the need for a trip to the outpatient ophthalmology clinic in 100% of encounters of patients with vision-threatening papilledema. Use of the VVF provided a more detailed, baseline examination at bedside in 61% of all encounters. A bedside pre- and postoperative visual field assessment was achieved in 14% of encounters. The VVF changed management in 70% of encounters. Conclusions: In our experience, use of the VVF has improved the quality of care for inpatients with neuro-ophthalmic conditions. A significant impact of the VVF was increased safety by preventing the need to transport patients to the outpatient setting for visual field monitoring, especially patients with vision-threatening papilledema and lumbar drains. The VVF made formal visual testing available to patients with mobility restrictions and patients undergoing neurosurgical procedures. Owing to improvement in quality of patient care, the VVF analyzer has become a mainstay of the examination of patients in the ED and hospital.
- 22 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (4) , 566-567
Comment: Anemia and Pseudotumor Cerebri: Absence of a Population-Level Association Does Not Negate Individual-Level Causation
Was not provided for this article.
- 22 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (4) , 566-567
Comment: Anemia and Pseudotumor Cerebri: Absence of a Population-Level Association Does Not Negate Individual-Level Causation
Was not provided for this article.
- Top Cited Papers
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 143 (3) , 215-220
Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide
Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications. Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide. Design, Setting, and Participants: This was a retrospective case series. All patients were initially seen in a community setting. Patients experiencing an ophthalmic complication in association with the use of semaglutide or tirzepatide were included in this analysis. Exposures: Patients described were using either semaglutide or tirzepatide. Main Outcomes and Measures: Visual acuity and visual field defects. Results: A total of 9 patients (mean [SD] age, 57.4 [11.6] years; age range, 37-77 years; 5 female [56%]; 4 male [44%]) were included in this study. Seven patients with nonarteritic ischemic anterior optic neuropathy, 1 patient with bilateral papillitis, and 1 patient with paracentral acute middle maculopathy were reported. Atypical features included sequential ischemic optic neuropathy, bilateral disc swelling at presentation, and progressive vision loss. Conclusions and Relevance: In this case series study, it was not possible to determine if there is a causal link between these drugs and the ophthalmic complications reported. In some cases, it is hypothesized that rapid correction of hyperglycemia induced by these drugs, rather than a toxic effect of the drugs, could be associated with the ophthalmic complications reported.
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 143 (3) , 215-220
Top Cited PapersOphthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide
Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications. Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide. Design, Setting, and Participants: This was a retrospective case series. All patients were initially seen in a community setting. Patients experiencing an ophthalmic complication in association with the use of semaglutide or tirzepatide were included in this analysis. Exposures: Patients described were using either semaglutide or tirzepatide. Main Outcomes and Measures: Visual acuity and visual field defects. Results: A total of 9 patients (mean [SD] age, 57.4 [11.6] years; age range, 37-77 years; 5 female [56%]; 4 male [44%]) were included in this study. Seven patients with nonarteritic ischemic anterior optic neuropathy, 1 patient with bilateral papillitis, and 1 patient with paracentral acute middle maculopathy were reported. Atypical features included sequential ischemic optic neuropathy, bilateral disc swelling at presentation, and progressive vision loss. Conclusions and Relevance: In this case series study, it was not possible to determine if there is a causal link between these drugs and the ophthalmic complications reported. In some cases, it is hypothesized that rapid correction of hyperglycemia induced by these drugs, rather than a toxic effect of the drugs, could be associated with the ophthalmic complications reported.
- Open Access
- 18 January 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 37, 102260
Enhancement within the orbits and superficial temporal artery: MRI clues to the diagnosis of giant cell arteritis
- 18 January 2025
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 37, 102260
Open AccessEnhancement within the orbits and superficial temporal artery: MRI clues to the diagnosis of giant cell arteritis
- Open Access
- 23 August 2024
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 36, 102143
Diagnostic dilemma: Leber's hereditary optic neuropathy in a 70-year-Old woman
- 23 August 2024
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 36, 102143
Open AccessDiagnostic dilemma: Leber's hereditary optic neuropathy in a 70-year-Old woman
- Open Access
- 13 March 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 64 (3) , 317-318
Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
Plain language summary: Idiopathic intracranial hypertension (IIH) is a condition of high pressure in the spinal fluid that is common in young women who are overweight or obese. Headache happens in most individuals with IIH and can continue after the early phase of IIH has resolved. We studied the use of a newer type of medication developed for migraine called calcitonin gene‐related peptide antibodies and we found that these medications can be helpful for patients who have had IIH, although studies with more patients will be helpful.
- 13 March 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 64 (3) , 317-318
Open AccessMigraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
Plain language summary: Idiopathic intracranial hypertension (IIH) is a condition of high pressure in the spinal fluid that is common in young women who are overweight or obese. Headache happens in most individuals with IIH and can continue after the early phase of IIH has resolved. We studied the use of a newer type of medication developed for migraine called calcitonin gene‐related peptide antibodies and we found that these medications can be helpful for patients who have had IIH, although studies with more patients will be helpful.
- Open Access
- 15 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5)
Issue Information
- 15 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5)
Open AccessIssue Information
- 4 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5) , 672-682
Validation of the Utah Photophobia Symptom Impact Scale (version 2) as a headache‐specific photophobia assessment tool
Objective: To present an updated version of the Utah Photophobia Symptom Impact Scale version 2 (UPSIS2), providing robust clinical and psychometric validation, to improve headache‐specific evaluation of light sensitivity and headache‐related photophobia. Background: The original UPSIS filled a gap in available tools for assessment of headache‐associated light sensitivity by providing patient‐reported evaluation of the impact of light sensitivity on activities of daily living (ADLs). We have since revised the original questionnaire to provide a more robust item construct and refined validation approach. Methods: We conducted a psychometric validation of the UPSIS2 through a primary analysis of an online survey of volunteers with recurrent headaches recruited from the University of Utah clinics and surrounding community. Volunteers completed the original UPSIS and UPSIS2 questionnaire versions in addition to measures of headache impact, disability, and frequency. The UPSIS2 now includes a pre‐defined recall period and a 1–4 Likert scale with standardized response anchors to improve clarity. Internal construct validity, external construct validity, and test–retest reliability, were evaluated. Results: Responses were obtained from 163 volunteers, with UPSIS2 scores ranging from 15 to 57 (out of a possible 15–60) with a mean (standard deviation) of 32.4 (8.80). Construct validity was satisfactory, as evidenced by sufficient unidimensionality, monotonicity, and local independence. Reliability was excellent, with Rasch test reliability = 0.90 and Cronbach's alpha = 0.92, and an intraclass correlation of 0.79 (95% confidence interval 0.65–0.88) for participants who took the test twice. UPSIS2 correlates well with other headache measures (Spearman's correlations >0.50), as well as the original UPSIS (Spearman's correlation = 0.87), indicating good convergent validity. UPSIS2 scores differ significantly across International Classification of Headache Disorders (third edition) groups, indicating good known group validity. Conclusion: The UPSIS2 provides a well‐validated headache‐specific outcome measure for the assessment of photophobia impact on ADLs.
- 4 May 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (5) , 672-682
Validation of the Utah Photophobia Symptom Impact Scale (version 2) as a headache‐specific photophobia assessment tool
Objective: To present an updated version of the Utah Photophobia Symptom Impact Scale version 2 (UPSIS2), providing robust clinical and psychometric validation, to improve headache‐specific evaluation of light sensitivity and headache‐related photophobia. Background: The original UPSIS filled a gap in available tools for assessment of headache‐associated light sensitivity by providing patient‐reported evaluation of the impact of light sensitivity on activities of daily living (ADLs). We have since revised the original questionnaire to provide a more robust item construct and refined validation approach. Methods: We conducted a psychometric validation of the UPSIS2 through a primary analysis of an online survey of volunteers with recurrent headaches recruited from the University of Utah clinics and surrounding community. Volunteers completed the original UPSIS and UPSIS2 questionnaire versions in addition to measures of headache impact, disability, and frequency. The UPSIS2 now includes a pre‐defined recall period and a 1–4 Likert scale with standardized response anchors to improve clarity. Internal construct validity, external construct validity, and test–retest reliability, were evaluated. Results: Responses were obtained from 163 volunteers, with UPSIS2 scores ranging from 15 to 57 (out of a possible 15–60) with a mean (standard deviation) of 32.4 (8.80). Construct validity was satisfactory, as evidenced by sufficient unidimensionality, monotonicity, and local independence. Reliability was excellent, with Rasch test reliability = 0.90 and Cronbach's alpha = 0.92, and an intraclass correlation of 0.79 (95% confidence interval 0.65–0.88) for participants who took the test twice. UPSIS2 correlates well with other headache measures (Spearman's correlations >0.50), as well as the original UPSIS (Spearman's correlation = 0.87), indicating good convergent validity. UPSIS2 scores differ significantly across International Classification of Headache Disorders (third edition) groups, indicating good known group validity. Conclusion: The UPSIS2 provides a well‐validated headache‐specific outcome measure for the assessment of photophobia impact on ADLs.
- 19 April 2022
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (4) , 495-501
Interdisciplinary Protocol for the Management of Vision-Threatening Papilledema
Background: This study evaluates the effectiveness of a multidisciplinary protocol for management of patients with papilledema and vision loss secondary to increased intracranial pressure. Methods: Retrospective record review of all adult patients who presented with vision-threatening papilledema (VTPE) and were treated under this protocol. Patients are admitted for lumbar drain placement and diuretics and followed daily to determine if they may be managed medically or require surgery (optic nerve sheath fenestration [ONSF] and/or cerebrospinal fluid [CSF] shunting). Results: Nineteen patients were included. Twelve had body mass index in the obese range and 6 were morbidly obese. Fourteen had idiopathic intracranial hypertension. Five had secondary pseudotumor cerebri syndrome related to medication use, dural venous sinus thrombosis, hypothyroidism, end-stage renal disease, pulmonary disease, and diastolic heart failure. Three patients did not require surgery and were discharged on oral diuretics; 3 patients underwent unilateral ONSF, 9 underwent bilateral ONSF, and 4 underwent bilateral ONSF followed by ventriculoperitoneal shunt placement. The average follow-up was 10.1 months. The visual acuity improved bilaterally in 12 patients and unilaterally in 4 patients. The remaining 3 patients had worsened vision in both eyes. Fifteen patients had bilateral improvement in their visual fields. Five eyes in 3 patients showed further constriction of the visual field at follow-up. Conclusions: We demonstrate how a multidisciplinary complex care protocol for treating VTPE can expedite and streamline treatment and restore vision. We found that most patients had improved symptoms and signs, including visual acuity, visual fields, and papilledema. We encourage institutions that manage VTPE to adopt similar institutional protocols.
- 19 April 2022
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (4) , 495-501
Interdisciplinary Protocol for the Management of Vision-Threatening Papilledema
Background: This study evaluates the effectiveness of a multidisciplinary protocol for management of patients with papilledema and vision loss secondary to increased intracranial pressure. Methods: Retrospective record review of all adult patients who presented with vision-threatening papilledema (VTPE) and were treated under this protocol. Patients are admitted for lumbar drain placement and diuretics and followed daily to determine if they may be managed medically or require surgery (optic nerve sheath fenestration [ONSF] and/or cerebrospinal fluid [CSF] shunting). Results: Nineteen patients were included. Twelve had body mass index in the obese range and 6 were morbidly obese. Fourteen had idiopathic intracranial hypertension. Five had secondary pseudotumor cerebri syndrome related to medication use, dural venous sinus thrombosis, hypothyroidism, end-stage renal disease, pulmonary disease, and diastolic heart failure. Three patients did not require surgery and were discharged on oral diuretics; 3 patients underwent unilateral ONSF, 9 underwent bilateral ONSF, and 4 underwent bilateral ONSF followed by ventriculoperitoneal shunt placement. The average follow-up was 10.1 months. The visual acuity improved bilaterally in 12 patients and unilaterally in 4 patients. The remaining 3 patients had worsened vision in both eyes. Fifteen patients had bilateral improvement in their visual fields. Five eyes in 3 patients showed further constriction of the visual field at follow-up. Conclusions: We demonstrate how a multidisciplinary complex care protocol for treating VTPE can expedite and streamline treatment and restore vision. We found that most patients had improved symptoms and signs, including visual acuity, visual fields, and papilledema. We encourage institutions that manage VTPE to adopt similar institutional protocols.